Skip to content

Study · Measured the body's own peptide · 2019

1 result

Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.

Hasan AA, von Websky K, Reichetzeder C, Tsuprykov O, Gaballa MMS, Guo J, Zeng S, Delić D, Tammen H, Klein T, Kleuser B, Hocher B

Kidney international27 Feb 2019Cited by 30 (Europe PMC)

PMID30979564 (opens in a new tab)DOI10.1016/j.kint.2019.01.010 (opens in a new tab)PepBankPUB-30979564
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In mice with 5/6 nephrectomy, linagliptin treatment significantly upregulated a thymosin β4-derived peptide in kidney proteomics.

    In plain wordsIn mice with kidney damage, the drug linagliptin raised the body's own thymosin beta‑4 peptide in the kidneys.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseKidney thymosin β4-derived peptide after linagliptin
    Study

    mousen: not reported in source

    wild-type and Glp1r-/- mice with 5/6 nephrectomy
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Treatment significantly upregulated three peptides derived from collagen alpha-1(I), thymosin β4 and heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) and significantly downregulated one peptide derived from Y box binding protein-1 (YB-1).
    2 context sentences
    Summary · context
    Here we investigated the renal effects of the DPP-4 inhibitor linagliptin in Glp1r-/- knock out and wild-type mice with 5/6 nephrectomy (5/6Nx).
    Summary · context
    Mice were allocated to groups: sham+wild type+placebo; 5/6Nx+ wild type+placebo; 5/6Nx+wild type+linagliptin; sham+knock out+placebo; 5/6Nx+knock out+ placebo; 5/6Nx+knock out+linagliptin.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.